BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 11896447)

  • 1. Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells.
    Scotlandi K; Maini C; Manara MC; Benini S; Serra M; Cerisano V; Strammiello R; Baldini N; Lollini PL; Nanni P; Nicoletti G; Picci P
    Cancer Gene Ther; 2002 Mar; 9(3):296-307. PubMed ID: 11896447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells.
    Scotlandi K; Avnet S; Benini S; Manara MC; Serra M; Cerisano V; Perdichizzi S; Lollini PL; De Giovanni C; Landuzzi L; Picci P
    Int J Cancer; 2002 Sep; 101(1):11-6. PubMed ID: 12209582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down-regulation of the insulin-like growth factor I receptor by antisense RNA can reverse the transformed phenotype of human cervical cancer cell lines.
    Nakamura K; Hongo A; Kodama J; Miyagi Y; Yoshinouchi M; Kudo T
    Cancer Res; 2000 Feb; 60(3):760-5. PubMed ID: 10676665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: therapeutic prospects.
    Benini S; Manara MC; Cerisano V; Perdichizzi S; Strammiello R; Serra M; Picci P; Scotlandi K
    Int J Cancer; 2004 Jan; 108(3):358-66. PubMed ID: 14648701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells.
    Benini S; Manara MC; Baldini N; Cerisano V; Massimo Serra ; Mercuri M; Lollini PL; Nanni P; Picci P; Scotlandi K
    Clin Cancer Res; 2001 Jun; 7(6):1790-7. PubMed ID: 11410521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo.
    Chernicky CL; Yi L; Tan H; Gan SU; Ilan J
    Cancer Gene Ther; 2000 Mar; 7(3):384-95. PubMed ID: 10766344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of IGF-I/IGF-IR circuit on the angiogenetic properties of Ewing's sarcoma cells.
    Strammiello R; Benini S; Manara MC; Perdichizzi S; Serra M; Spisni E; Picci P; Scotlandi K
    Horm Metab Res; 2003; 35(11-12):675-84. PubMed ID: 14710346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphoinositide 3-hydroxide kinase blockade enhances apoptosis in the Ewing's sarcoma family of tumors.
    Toretsky JA; Thakar M; Eskenazi AE; Frantz CN
    Cancer Res; 1999 Nov; 59(22):5745-50. PubMed ID: 10582694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of murine breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor decreases the level of plasminogen activator transcripts, inhibits cell growth in vitro, and reduces tumorigenesis in vivo.
    Chernicky CL; Tan H; Yi L; Loret de Mola JR; Ilan J
    Mol Pathol; 2002 Apr; 55(2):102-9. PubMed ID: 11950959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo.
    Burfeind P; Chernicky CL; Rininsland F; Ilan J; Ilan J
    Proc Natl Acad Sci U S A; 1996 Jul; 93(14):7263-8. PubMed ID: 8692980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone: effects on insulin-like growth factor II.
    Braczkowski R; Schally AV; Plonowski A; Varga JL; Groot K; Krupa M; Armatis P
    Cancer; 2002 Oct; 95(8):1735-45. PubMed ID: 12365022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blockade of the type I IGF receptor expression in human prostate cancer cells inhibits proliferation and invasion, up-regulates IGF binding protein-3, and suppresses MMP-2 expression.
    Grzmil M; Hemmerlein B; Thelen P; Schweyer S; Burfeind P
    J Pathol; 2004 Jan; 202(1):50-9. PubMed ID: 14694521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapies in Ewing's sarcoma.
    Scotlandi K
    Adv Exp Med Biol; 2006; 587():13-22. PubMed ID: 17163152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival.
    Picarda G; Lamoureux F; Geffroy L; Delepine P; Montier T; Laud K; Tirode F; Delattre O; Heymann D; Rédini F
    Clin Cancer Res; 2010 Apr; 16(8):2363-74. PubMed ID: 20371692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing's sarcoma cell line, TC-71.
    Manara MC; Perdichizzi S; Serra M; Pierini R; Benini S; Hattinger CM; Astolfi A; Bagnati R; D'Incalci M; Picci P; Scotlandi K
    Int J Oncol; 2005 Dec; 27(6):1605-16. PubMed ID: 16273217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.
    Murakami T; Singh AS; Kiyuna T; Dry SM; Li Y; James AW; Igarashi K; Kawaguchi K; DeLong JC; Zhang Y; Hiroshima Y; Russell T; Eckardt MA; Yanagawa J; Federman N; Matsuyama R; Chishima T; Tanaka K; Bouvet M; Endo I; Eilber FC; Hoffman RM
    Oncotarget; 2016 Jul; 7(30):47556-47564. PubMed ID: 27286459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of rat C6 glioblastoma tumor growth by expression of insulin-like growth factor I receptor antisense mRNA.
    Resnicoff M; Li W; Basak S; Herlyn D; Baserga R; Rubin R
    Cancer Immunol Immunother; 1996 Jan; 42(1):64-8. PubMed ID: 8625368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical in vivo study of new insulin-like growth factor-I receptor--specific inhibitor in Ewing's sarcoma.
    Manara MC; Landuzzi L; Nanni P; Nicoletti G; Zambelli D; Lollini PL; Nanni C; Hofmann F; García-Echeverría C; Picci P; Scotlandi K
    Clin Cancer Res; 2007 Feb; 13(4):1322-30. PubMed ID: 17317844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid.
    Neuenschwander S; Roberts CT; LeRoith D
    Endocrinology; 1995 Oct; 136(10):4298-303. PubMed ID: 7664648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [shRNA-mediated insulin-like growth factor I receptor gene silencing inhibits cell proliferation, induces cell apoptosis, and suppresses tumor growth in non-small cell lung cancer: in vitro and in vivo experiments].
    Dong AQ; Kong MJ; Ma ZY; Qian JF; Fan JQ; Xu XH
    Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(21):1506-9. PubMed ID: 17785094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.